Business
Dr. Alex McPherson Steps Down as President and CEO of Biomira
Dr. Alex McPherson Steps Down as President and CEO of Biomira.
About this update from Skrr Exploration, Inc.
[{"type":"text","content":"\n\n\n\n\n--Company Initiates Search for New CEO --\n\nEDMONTON, April 3 /CNW/ - Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) today\nannounced that Alex McPherson, M.D., Ph.D. will step down as the Company's\nPresident and Chief Executive Officer following the Annual General Meeting\nscheduled for May 17, 2006. The Board has initiated a search process for\nDr. McPherson's successor. Edward Taylor, the Company's Chief Financial\nOfficer and Vice President Finance and Administration, has agreed to assume\nthe role of President and Chief Executive Officer on an interim basis, if a\nsuccessor has not been identified by the date of Dr. McPherson's departure.\nThe Board expressed its appreciation to Dr. McPherson for the key\nleadership role he has played in the Company's development since he joined the\nCompany in 1991 as the President and CEO and his prior involvement with the\nBoard.\nEric Baker, the Company's Chairman, commented, \"We would like to thank\nAlex for his tireless work and dedication to Biomira. He leaves the Company as\nBiomira enters an exciting stage in its lifecycle. As a result of the recent\nMerck KGaA transaction, Biomira can now embark on a new path and we believe we\nhave the resources to focus on growing our pipeline and leveraging our\nscientific expertise in the development of peptide-based synthetic-defined\nantigen vaccines.\"\nDr. McPherson commented, \"Biomira has been an important part of my life\nfor the past 20 years. The Company has always been committed to the\ndevelopment of products for the treatment of cancer and I am glad to depart\nwith our lead product for non-small cell lung cancer, L-BLP25, poised to\ncommence a phase 3 trial this summer and in the hands of Merck KGaA.\"\n\nAbout Biomira\nBiomira is a biotechnology company specializing in the development of\ninnovative therapeutic approaches to cancer management. Biomira's commitment\nto the treatment of cancer currently focuses on the development of synthetic\nvaccines and novel strategies for cancer immunotherapy.\n\nThis release may contain forward-looking statements. Various factors\ncould cause actual results to differ materially from those projected in\nforward-looking statements, including those predicting the timing of clinical\ntrials, particularly the phase 3 clinical trial of L-BLP25 and the ability of\nBiomira to acquire new pipeline...